🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

404 results for “treatment” Clear

  1. Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Allergic Rhinitis

    approved small molecule active

    1 trial

  2. Ketamine

    Teva Pharma GmbH

    Treatment Resistant Depression

    approved small molecule active

    1 trial

  3. ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg sol

    The George Institute

    Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.

    approved small molecule active

    1 trial

  4. Optimal hypoglycemic treatment

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved other active

    1 trial

  5. Rapid Acting insulin with pre-treatment of rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  6. Reinforcement Based Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    approved other completed

    1 trial

  7. Telbivudine treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Hepatitis B

    approved small molecule completed

    1 trial

  8. Treatment Algorithm A

    Takeda

    Colitis, Ulcerative

    approved mab active

    1 trial

  9. Treatment group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypertension

    approved small molecule completed

    1 trial

  10. XALKORI 200 mg hard capsules, XALKORI 250 mg hard capsules, Crizotinib 200 mg capsules, Crizotinib 250 mg capsules

    Pfizer Australia Pty Ltd

    This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed

    approved small molecule active

    1 trial

  11. biologics treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Psoriasis

    approved mab active

    1 trial

  12. physiotherapeutic treatment

    Universal Integrated

    Morquio's Disease

    approved other terminated

    1 trial

  13. treatment with CAZ-AVI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Patients With Critically Ill Infections

    approved small molecule active

    1 trial

  14. Antioxidant

    AYTU BIOPHARMA, INC

    Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man)

    other terminated

    1 trial

  15. BXD treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    IBD - Inflammatory Bowel Disease

    small molecule completed

    1 trial

  16. Basic treatment

    The First People's Hospital of Lianyungang

    Major Depressive Disorder

    small molecule completed

    1 trial

  17. Basic treatment

    Jian Li

    Major Depressive Disorder

    small molecule completed

    1 trial

  18. Conservative treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Pancreatitis

    small molecule active

    1 trial

  19. Control (Standard treatment)

    Grace Therapeutics

    Moisture Associated Skin Damage

    small molecule active

    1 trial

  20. Conventional treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Copd Exacerbation Acute

    small molecule completed

    1 trial

  21. Dapagliflozin Treatment Group

    The First People's Hospital of Lianyungang

    Atrial Fibrillation (AF)

    small molecule active

    1 trial

  22. Drug treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prolactinoma

    small molecule active

    1 trial

  23. Ferrous Fumarate Oral Tablet

    Hospital Authority, Hong Kong

    Iron Deficiency Anemia Treatment

    small molecule active

    1 trial

  24. HCQ/CQ and CAB combined treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resistance, Disease

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources